[1]
C. Clarke, R. Howard, M. Rossor, and S. D. Shorvon, Eds., Neurology: a Queen Square textbook, Second edition. Chichester, West Sussex, UK: Wiley Blackwell, 2016 [Online]. Available: https://onlinelibrary.wiley.com/doi/book/10.1002/9781118486160
[2]
R. A. McCarthy and E. K. Warrington, Cognitive neuropsychology: a clinical introduction. San Diego, California: Academic Press, Inc, 1990 [Online]. Available: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618430004761&institutionId=4761&customerId=4760
[3]
M. Rossor and J. H. Growdon, The dementias 2. [Place of publication not identified]: Butterworth Heinemann/Elsevier, 2007 [Online]. Available: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618250004761&institutionId=4761&customerId=4760
[4]
J. R. Hodges, Cognitive assessment for clinicians, 3 ed. [Oxford]: Oxford University Press, 2017 [Online]. Available: http://dx.doi.org/10.1093/med/9780198749189.001.0001
[5]
E. R. Kandel, J. H. Schwartz, T. M. Jessell, S. Siegelbaum, and A. J. Hudspeth, Eds., Principles of neural science, Fifth edition. New York: McGraw Hill Medical, 2013 [Online]. Available: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605810004761&institutionId=4761&customerId=4760
[6]
M. Husain, Oxford textbook of cognitive neurology and dementia. [Oxford]: Oxford University Press, 2016 [Online]. Available: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605720004761&institutionId=4761&customerId=4760
[7]
‘Alzheimer’s Facts and Figures Report | Alzheimer’s Association’. [Online]. Available: https://www.alz.org/alzheimers-dementia/facts-figures
[8]
D. J. Selkoe and J. Hardy, ‘The amyloid hypothesis of Alzheimer’s disease at 25 years’, EMBO Molecular Medicine, vol. 8, no. 6, pp. 595–608, Jun. 2016, doi: 10.15252/emmm.201606210.
[9]
B. Dubois et al., ‘Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria’, The Lancet Neurology, vol. 13, no. 6, pp. 614–629, Jun. 2014, doi: 10.1016/S1474-4422(14)70090-0.
[10]
C. T. Loy, P. R. Schofield, A. M. Turner, and J. B. Kwok, ‘Genetics of dementia’, The Lancet, vol. 383, no. 9919, pp. 828–840, Mar. 2014, doi: 10.1016/S0140-6736(13)60630-3.
[11]
E. Karran and J. Hardy, ‘Antiamyloid Therapy for Alzheimer’s Disease — Are We on the Right Road?’, New England Journal of Medicine, vol. 370, no. 4, pp. 377–378, Jan. 2014, doi: 10.1056/NEJMe1313943.
[12]
K. A. Johnson, N. C. Fox, R. A. Sperling, and W. E. Klunk, ‘Brain Imaging in Alzheimer Disease’, Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 4, pp. a006213–a006213, Apr. 2012, doi: 10.1101/cshperspect.a006213.
[13]
C. A. Ross et al., ‘Huntington disease: natural history, biomarkers and prospects for therapeutics’, Nature Reviews Neurology, vol. 10, no. 4, pp. 204–216, Apr. 2014, doi: 10.1038/nrneurol.2014.24.
[14]
G. P. Bates et al., ‘Huntington disease’, Nature Reviews Disease Primers, Apr. 2015, doi: 10.1038/nrdp.2015.5.
[15]
E. J. Wild and S. J. Tabrizi, ‘Therapies targeting DNA and RNA in Huntington’s disease’, The Lancet Neurology, vol. 16, no. 10, pp. 837–847, Oct. 2017, doi: 10.1016/S1474-4422(17)30280-6.
[16]
J. B. Carroll, G. P. Bates, J. Steffan, C. Saft, and S. J. Tabrizi, ‘Treating the whole body in Huntington’s disease’, The Lancet Neurology, vol. 14, no. 11, pp. 1135–1142, Nov. 2015, doi: 10.1016/S1474-4422(15)00177-5.
[17]
S. J. Tabrizi et al., ‘Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis’, The Lancet Neurology, vol. 10, no. 1, pp. 31–42, Jan. 2011, doi: 10.1016/S1474-4422(10)70276-3.
[18]
S. J. Tabrizi et al., ‘Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data’, The Lancet Neurology, vol. 11, no. 1, pp. 42–53, Jan. 2012, doi: 10.1016/S1474-4422(11)70263-0.
[19]
S. J. Tabrizi et al., ‘Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data’, The Lancet Neurology, vol. 12, no. 7, pp. 637–649, Jul. 2013, doi: 10.1016/S1474-4422(13)70088-7.
[20]
L. Jones, H. Houlden, and S. J. Tabrizi, ‘DNA repair in the trinucleotide repeat disorders’, The Lancet Neurology, vol. 16, no. 1, pp. 88–96, Jan. 2017, doi: 10.1016/S1474-4422(16)30350-7.
[21]
M. Rossor et al., ‘Dementia and Cognitive Impairment’, in Neurology, C. Clarke, R. Howard, M. Rossor, and S. Shorvon, Eds. Chichester, UK: John Wiley & Sons, Ltd, 2016, pp. 289–336 [Online]. Available: http://doi.wiley.com/10.1002/9781118486160.ch8
[22]
M. N. Rossor, N. C. Fox, C. J. Mummery, J. M. Schott, and J. D. Warren, ‘The diagnosis of young-onset dementia’, The Lancet Neurology, vol. 9, no. 8, pp. 793–806, Aug. 2010, doi: 10.1016/S1474-4422(10)70159-9.
[23]
J. M. Schott, N. C. Fox, and M. N. Rossor, ‘Assessment and investigation of the cognitively impaired adult’, in Oxford Textbook of Cognitive Neurology and Dementia, M. Husain and J. M. Schott, Eds. Oxford University Press, 2016, pp. 221–230 [Online]. Available: http://oxfordmedicine.com/view/10.1093/med/9780199655946.001.0001/med-9780199655946-chapter-21
[24]
A. J. E. Green, ‘RT-QuIC: a new test for sporadic CJD’, Practical Neurology, Oct. 2018, doi: 10.1136/practneurol-2018-001935.
[25]
J. Collinge, ‘Mammalian prions and their wider relevance in neurodegenerative diseases’, Nature, vol. 539, no. 7628, pp. 217–226, Nov. 2016, doi: 10.1038/nature20415.
[26]
S. Mead and P. Rudge, ‘CJD mimics and chameleons’, Practical Neurology, vol. 17, no. 2, pp. 113–121, Apr. 2017, doi: 10.1136/practneurol-2016-001571.
[27]
Z. Walker, K. L. Possin, B. F. Boeve, and D. Aarsland, ‘Lewy body dementias’, The Lancet, vol. 386, no. 10004, pp. 1683–1697, Oct. 2015, doi: 10.1016/S0140-6736(15)00462-6.
[28]
G. M. Halliday, J. L. Holton, T. Revesz, and D. W. Dickson, ‘Neuropathology underlying clinical variability in patients with synucleinopathies’, Acta Neuropathologica, vol. 122, no. 2, pp. 187–204, Aug. 2011, doi: 10.1007/s00401-011-0852-9.
[29]
R. A. Barker and C. H. Williams-Gray, ‘Review: The spectrum of clinical features seen with alpha synuclein pathology’, Neuropathology and Applied Neurobiology, vol. 42, no. 1, pp. 6–19, Feb. 2016, doi: 10.1111/nan.12303.
[30]
J. Bras et al., ‘Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies’, Human Molecular Genetics, vol. 23, no. 23, pp. 6139–6146, Dec. 2014, doi: 10.1093/hmg/ddu334.
[31]
I. G. McKeith et al., ‘Diagnosis and management of dementia with Lewy bodies’, Neurology, vol. 89, no. 1, pp. 88–100, Jul. 2017, doi: 10.1212/WNL.0000000000004058.
[32]
R. S. Weil, T. L. Lashley, J. Bras, A. E. Schrag, and J. M. Schott, ‘Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies’, F1000Research, vol. 6, Aug. 2017, doi: 10.12688/f1000research.11725.1.
[33]
I. O. C. Woollacott and J. D. Rohrer, ‘The clinical spectrum of sporadic and familial forms of frontotemporal dementia’, Journal of Neurochemistry, vol. 138, pp. 6–31, Aug. 2016, doi: 10.1111/jnc.13654.
[34]
E. Gordon, J. D. Rohrer, and N. C. Fox, ‘Advances in neuroimaging in frontotemporal dementia’, Journal of Neurochemistry, vol. 138, pp. 193–210, Aug. 2016, doi: 10.1111/jnc.13656.
[35]
R. M. Ahmed et al., ‘Neuronal network disintegration: common pathways linking neurodegenerative diseases’, Journal of Neurology, Neurosurgery & Psychiatry, vol. 87, no. 11, pp. 1234–1241, Nov. 2016, doi: 10.1136/jnnp-2014-308350.
[36]
P. D. Fletcher and J. D. Warren, ‘Semantic Dementia: a specific network-opathy’, Journal of Molecular Neuroscience, vol. 45, no. 3, pp. 629–636, Nov. 2011, doi: 10.1007/s12031-011-9586-3.
[37]
J. C. Goll et al., ‘Non-verbal sound processing in the primary progressive aphasias’, Brain, vol. 133, no. 1, pp. 272–285, Jan. 2010, doi: 10.1093/brain/awp235.
[38]
J. C. Goll, G. R. Ridgway, S. J. Crutch, F. E. Theunissen, and J. D. Warren, ‘Nonverbal sound processing in semantic dementia: A functional MRI study’, NeuroImage, vol. 61, no. 1, pp. 170–180, May 2012, doi: 10.1016/j.neuroimage.2012.02.045.
[39]
M. L. Gorno-Tempini et al., ‘Classification of primary progressive aphasia and its variants’, Neurology, vol. 76, no. 11, pp. 1006–1014, Mar. 2011, doi: 10.1212/WNL.0b013e31821103e6.
[40]
M. Grossman, ‘The non-fluent/agrammatic variant of primary progressive aphasia’, The Lancet Neurology, vol. 11, no. 6, pp. 545–555, Jun. 2012, doi: 10.1016/S1474-4422(12)70099-6.
[41]
C. E. Leyton, J. R. Hodges, C. A. McLean, J. J. Kril, O. Piguet, and K. J. Ballard, ‘Is the logopenic-variant of primary progressive aphasia a unitary disorder?’, Cortex, vol. 67, pp. 122–133, Jun. 2015, doi: 10.1016/j.cortex.2015.03.011.
[42]
C. R. Marshall et al., ‘Primary progressive aphasia: a clinical approach’, Journal of Neurology, vol. 265, no. 6, pp. 1474–1490, Jun. 2018, doi: 10.1007/s00415-018-8762-6.
[43]
J. D. Rohrer, W. D. Knight, J. E. Warren, N. C. Fox, M. N. Rossor, and J. D. Warren, ‘Word-finding difficulty: a clinical analysis of the progressive aphasias’, Brain, vol. 131, no. 1, pp. 8–38, Dec. 2007, doi: 10.1093/brain/awm251.
[44]
J. D. Rohrer et al., ‘Progressive logopenic/phonological aphasia: Erosion of the language network’, NeuroImage, vol. 49, no. 1, pp. 984–993, Jan. 2010, doi: 10.1016/j.neuroimage.2009.08.002.
[45]
J. D. Rohrer, M. N. Rossor, and J. D. Warren, ‘Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis’, Neurology, vol. 75, no. 7, pp. 603–610, Aug. 2010, doi: 10.1212/WNL.0b013e3181ed9c6b.
[46]
J. D. Rohrer, D. Sauter, S. Scott, M. N. Rossor, and J. D. Warren, ‘Receptive prosody in nonfluent primary progressive aphasias’, Cortex, vol. 48, no. 3, pp. 308–316, Mar. 2012, doi: 10.1016/j.cortex.2010.09.004.
[47]
J. D. Warren, J. D. Rohrer, and M. N. Rossor, ‘Frontotemporal dementia’, BMJ, vol. 347, no. aug12 3, pp. f4827–f4827, Aug. 2013, doi: 10.1136/bmj.f4827.
[48]
D. S. Lynch et al., ‘Clinical and genetic characterization of leukoencephalopathies in adults’, Brain, vol. 140, no. 5, pp. 1204–1211, May 2017, doi: 10.1093/brain/awx045.
[49]
C. E. M. Hollak and R. Lachmann, Eds., Inherited metabolic disease in adults: a clinical guide. [New York]: Oxford University Press, 2016 [Online]. Available: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3043210560004761&institutionId=4761&customerId=4760
[50]
E. Devenney, S. Vucic, J. R. Hodges, and M. C. Kiernan, ‘Motor neuron disease-frontotemporal dementia: a clinical continuum’, Expert Review of Neurotherapeutics, vol. 15, no. 5, pp. 509–522, May 2015, doi: 10.1586/14737175.2015.1034108.
[51]
M. J. Strong et al., ‘Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria’, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 18, no. 3–4, pp. 153–174, Apr. 2017, doi: 10.1080/21678421.2016.1267768.
[52]
A. Iranzo et al., ‘Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients’, PLoS ONE, vol. 9, no. 2, Feb. 2014, doi: 10.1371/journal.pone.0089741.
[53]
S. A. Kielb, S. Ancoli-Israel, G. W. Rebok, and A. P. Spira, ‘Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment’, NeuroMolecular Medicine, vol. 14, no. 3, pp. 180–193, Sep. 2012, doi: 10.1007/s12017-012-8182-1.
[54]
B. A. Mander, J. R. Winer, W. J. Jagust, and M. P. Walker, ‘Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer’s Disease?’, Trends in Neurosciences, vol. 39, no. 8, pp. 552–566, Aug. 2016, doi: 10.1016/j.tins.2016.05.002.
[55]
S. J. McCarter, E. K. St. Louis, and B. F. Boeve, ‘Sleep Disturbances in Frontotemporal Dementia’, Current Neurology and Neuroscience Reports, vol. 16, no. 9, Sep. 2016, doi: 10.1007/s11910-016-0680-3.
[56]
S. Ooms and Y.-E. Ju, ‘Treatment of Sleep Disorders in Dementia’, Current Treatment Options in Neurology, vol. 18, no. 9, Sep. 2016, doi: 10.1007/s11940-016-0424-3.
[57]
C. J. D. Hardy et al., ‘Hearing and dementia’, Journal of Neurology, vol. 263, no. 11, pp. 2339–2354, Nov. 2016, doi: 10.1007/s00415-016-8208-y.
[58]
G. Livingston et al., ‘Dementia prevention, intervention, and care’, The Lancet, vol. 390, no. 10113, pp. 2673–2734, Dec. 2017, doi: 10.1016/S0140-6736(17)31363-6.
[59]
J. C. Goll, S. J. Crutch, and J. D. Warren, ‘Central auditory disorders: toward a neuropsychology of auditory objects’, Current Opinion in Neurology, vol. 23, no. 6, pp. 617–627, Dec. 2010, doi: 10.1097/WCO.0b013e32834027f6.
[60]
M. Husain, Oxford textbook of cognitive neurology and dementia. [Oxford]: Oxford University Press, 2016 [Online]. Available: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3119511110004761&institutionId=4761&customerId=4760
[61]
K. Blennow, J. Hardy, and H. Zetterberg, ‘The Neuropathology and Neurobiology of Traumatic Brain Injury’, Neuron, vol. 76, no. 5, pp. 886–899, Dec. 2012, doi: 10.1016/j.neuron.2012.11.021.
[62]
D. H. Smith, V. E. Johnson, and W. Stewart, ‘Chronic neuropathologies of single and repetitive TBI: substrates of dementia?’, Nature Reviews Neurology, vol. 9, no. 4, pp. 211–221, Apr. 2013, doi: 10.1038/nrneurol.2013.29.
[63]
A. C. McKee et al., ‘The spectrum of disease in chronic traumatic encephalopathy’, Brain, vol. 136, no. 1, pp. 43–64, Jan. 2013, doi: 10.1093/brain/aws307.
[64]
S. Fleminger, ‘Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial replication’, Journal of Neurology, Neurosurgery & Psychiatry, vol. 74, no. 7, pp. 857–862, Jul. 2003, doi: 10.1136/jnnp.74.7.857.
[65]
G. Scott et al., ‘Amyloid pathology and axonal injury after brain trauma’, Neurology, vol. 86, no. 9, pp. 821–828, Mar. 2016, doi: 10.1212/WNL.0000000000002413.
[66]
‘Hereditary and sporadic beta-amyloidoses’. [Online]. Available: https://www.bioscience.org/2013/v18/af/4173/fulltext.htm
[67]
G. V. W. Johnson, ‘Tau phosphorylation in neuronal cell function and dysfunction’, Journal of Cell Science, vol. 117, no. 24, pp. 5721–5729, Nov. 2004, doi: 10.1242/jcs.01558.
[68]
T. Revesz et al., ‘Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies’, Acta Neuropathologica, vol. 118, no. 1, pp. 115–130, Jul. 2009, doi: 10.1007/s00401-009-0501-8.
[69]
T. J. Montine et al., ‘National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach’, Acta Neuropathologica, vol. 123, no. 1, pp. 1–11, Jan. 2012, doi: 10.1007/s00401-011-0910-3.
[70]
D. R. Thal, ‘Neurodegeneration in Normal Brain Aging and Disease’, Science of Aging Knowledge Environment, vol. 2004, no. 23, pp. pe26–pe26, Jun. 2004, doi: 10.1126/sageke.2004.23.pe26.
[71]
H. Braak and E. Braak, ‘Staging of alzheimer’s disease-related neurofibrillary changes’, Neurobiology of Aging, vol. 16, no. 3, pp. 271–278, May 1995, doi: 10.1016/0197-4580(95)00021-6.
[72]
S. S. Mirra et al., ‘The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease’, Neurology, vol. 41, no. 4, pp. 479–479, Apr. 1991, doi: 10.1212/WNL.41.4.479.
[73]
T. J. Montine et al., ‘National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach’, Acta Neuropathologica, vol. 123, no. 1, pp. 1–11, Jan. 2012, doi: 10.1007/s00401-011-0910-3.
[74]
R. Dobson and D. Alvares, ‘The difficulties with vitamin B’, Practical Neurology, vol. 16, no. 4, pp. 308–311, Aug. 2016, doi: 10.1136/practneurol-2015-001344.
[75]
Jonathan Carr, ‘Neurosyphilis’, Practical Neurology, vol. 3, pp. 328–341, Dec. 2003 [Online]. Available: https://pn.bmj.com/content/3/6/328
[76]
F. Graus et al., ‘A clinical approach to diagnosis of autoimmune encephalitis’, The Lancet Neurology, vol. 15, no. 4, pp. 391–404, Apr. 2016, doi: 10.1016/S1474-4422(15)00401-9.
[77]
C. Salvarani, R. D. Brown, and G. G. Hunder, ‘Adult primary central nervous system vasculitis’, The Lancet, vol. 380, no. 9843, pp. 767–777, Aug. 2012, doi: 10.1016/S0140-6736(12)60069-5.
[78]
J. J. Halperin, R. Kurlan, J. M. Schwalb, M. D. Cusimano, G. Gronseth, and D. Gloss, ‘Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response’, Neurology, vol. 85, no. 23, pp. 2063–2071, Dec. 2015, doi: 10.1212/WNL.0000000000002193.
[79]
Arash Asher, ‘The effect of cancer treatment on cognitive function.’, undefined [Online]. Available: https://www.semanticscholar.org/paper/The-effect-of-cancer-treatment-on-cognitive-Asher-Myers/6bdd550dab6cfad0714aa76dd2ee439ad983e4be
[80]
F. Graus et al., ‘A clinical approach to diagnosis of autoimmune encephalitis’, The Lancet Neurology, vol. 15, no. 4, pp. 391–404, Apr. 2016, doi: 10.1016/S1474-4422(15)00401-9.
[81]
‘Cognitive Impairment Associated with Cancer: A Brief Review’, Innovations in Clinical Neuroscience, vol. 15, no. 1–2, 2018 [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819720/
[82]
L. J. Haddow, J. D. Cartledge, and H. Manji, ‘HIV and the brain: from AIDS to old age’, Clinical Medicine, vol. 13, no. Suppl_6, pp. s24–s28, Dec. 2013, doi: 10.7861/clinmedicine.13-6-s24.
[83]
S. Nightingale, B. D. Michael, S. Defres, L. A. Benjamin, and T. Solomon, ‘Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed’, Practical Neurology, vol. 13, no. 6, pp. 354–356, Dec. 2013, doi: 10.1136/practneurol-2013-000689.
[84]
‘HIV in the United Kingdom 2016 infographic’. [Online]. Available: https://www.gov.uk/government/publications/hiv-in-the-united-kingdom
[85]
R. F. Itzhaki et al., ‘Microbes and Alzheimer’s Disease’, Journal of Alzheimer’s Disease, vol. 51, no. 4, pp. 979–984, Apr. 2016, doi: 10.3233/JAD-160152.
[86]
S. Nightingale et al., ‘Controversies in HIV-associated neurocognitive disorders’, The Lancet Neurology, vol. 13, no. 11, pp. 1139–1151, Nov. 2014, doi: 10.1016/S1474-4422(14)70137-1.
[87]
Richard W. Price and Bruce J. Brew, ‘The AIDS Dementia Complex’, The Journal of Infectious Diseases, vol. 158, no. 5, 1988 [Online]. Available: https://www.jstor.org/stable/30136610?seq=1#metadata_info_tab_contents
[88]
‘UK National Guidelines for HIV Testing 2008’. [Online]. Available: https://www.bhiva.org/HIV-testing-guidelines
[89]
L. Zhou, M. Miranda-Saksena, and N. K. Saksena, ‘Viruses and neurodegeneration’, Virology Journal, vol. 10, no. 1, 2013, doi: 10.1186/1743-422X-10-172.
[90]
G. De Chiara et al., ‘Infectious Agents and Neurodegeneration’, Molecular Neurobiology, vol. 46, no. 3, pp. 614–638, Dec. 2012, doi: 10.1007/s12035-012-8320-7.
[91]
K. A. Wendorf et al., ‘Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated’, Clinical Infectious Diseases, vol. 65, no. 2, pp. 226–232, Jul. 2017, doi: 10.1093/cid/cix302.
[92]
K. G. Ghanem, ‘REVIEW: Neurosyphilis: A Historical Perspective and Review’, CNS Neuroscience & Therapeutics, vol. 16, no. 5, pp. e157–e168, Oct. 2010, doi: 10.1111/j.1755-5949.2010.00183.x.
[93]
O. Somasundaram, ‘Neuro syphilis: Portrayals by Sir Arthur Conan Doyle’, Indian Journal of Psychiatry, vol. 51, no. 3, 2009, doi: 10.4103/0019-5545.55103.
[94]
V. Hachinski et al., ‘National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards’, Stroke, vol. 37, no. 9, pp. 2220–2241, Sep. 2006, doi: 10.1161/01.STR.0000237236.88823.47.
[95]
P. B. Gorelick et al., ‘Vascular Contributions to Cognitive Impairment and Dementia’, Stroke, vol. 42, no. 9, pp. 2672–2713, Sep. 2011, doi: 10.1161/STR.0b013e3182299496.
[96]
‘Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales’, The Lancet, vol. 357, no. 9251, pp. 169–175, Jan. 2001, doi: 10.1016/S0140-6736(00)03589-3.
[97]
D. Leys, H. Hénon, M.-A. Mackowiak-Cordoliani, and F. Pasquier, ‘Poststroke dementia’, The Lancet Neurology, vol. 4, no. 11, pp. 752–759, Nov. 2005, doi: 10.1016/S1474-4422(05)70221-0.
[98]
J. T. O’Brien and A. Thomas, ‘Vascular dementia’, The Lancet, vol. 386, no. 10004, pp. 1698–1706, Oct. 2015, doi: 10.1016/S0140-6736(15)00463-8.
